Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.

Al-Momani H, Barnes R, El-Hadi A, Shah R, Lewis WG, Edwards P.

World J Gastroenterol. 2012 Nov 28;18(44):6447-51; discussion p.6450. doi: 10.3748/wjg.v18.i44.6447.

2.

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.

He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q.

World J Gastroenterol. 2013;19(14):2171-8. doi: 10.3748/wjg.v19.i14.2171.

3.

Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.

Tanaka T, Fujimura A, Ichimura K, Yanai H, Sato Y, Takata K, Okada H, Kawano S, Tanabe S, Yoshino T.

World J Gastroenterol. 2012 Nov 21;18(43):6263-8. doi: 10.3748/wjg.v18.i43.6263.

4.

HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.

Nagaraja V, Shaw N, Morey AL, Cox MR, Eslick GD.

Eur J Surg Oncol. 2016 Jan;42(1):140-8. doi: 10.1016/j.ejso.2015.08.159. Epub 2015 Sep 10.

PMID:
26422587
5.

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

Langer R, Rauser S, Feith M, Nährig JM, Feuchtinger A, Friess H, Höfler H, Walch A.

Mod Pathol. 2011 Jul;24(7):908-16. doi: 10.1038/modpathol.2011.52. Epub 2011 Apr 22.

6.

Overexpression of her-2 associated with the progression of esophageal cancer patients.

Wang G, Zhang W, Jiang W, Luan L.

Hepatogastroenterology. 2013 Nov-Dec;60(128):1972-8.

PMID:
24719937
7.

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.

Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G.

Mod Pathol. 2007 Jan;20(1):120-9. Epub 2006 Nov 24.

8.

Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis.

Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J, Alderson D.

Eur J Surg Oncol. 1997 Feb;23(1):30-5.

PMID:
9066744
9.
10.

Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study.

Schena M, La Rovere E, Solerio D, Bustreo S, Barone C, Daniele L, Buffoni L, Bironzo P, Sapino A, Gasparri G, Ciuffreda L, Ricardi U.

Tumori. 2012 Jul-Aug;98(4):451-7. doi: 10.1700/1146.12639.

PMID:
23052161
11.

Chemo-radiotherapy in locally advanced squamous cell oesophageal cancer--are upper third tumours more responsive?

Papp A, Cseke L, Farkas R, Pavlovics G, Horvath G, Varga G, Szigeti A, Bellyei S, Marton S, Poto L, Kalmar K, Vereczkei A, Pozsgai E, Horvath OP.

Pathol Oncol Res. 2010 Jun;16(2):193-200. doi: 10.1007/s12253-009-9206-5. Epub 2009 Sep 17.

PMID:
19760123
12.

Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.

König AM, Reeh M, Dancau AM, Rathjens M, Gros S, Uzunoglu FG, Bockhorn M, Simon R, Sauter G, Marx A, Izbicki JR.

Anticancer Res. 2013 Nov;33(11):4975-82.

PMID:
24222138
13.

Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.

Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, Mori M, Doki Y.

Gastric Cancer. 2015 Oct;18(4):691-7. doi: 10.1007/s10120-014-0430-7. Epub 2014 Sep 16.

PMID:
25224659
14.

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Boers JE, Meeuwissen H, Methorst N.

Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. Epub 2011 Feb 16.

15.

HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Uehara T, Fujimoto M, Tsuruyama T, Date H, Haga H.

Lung Cancer. 2014 Sep;85(3):373-8. doi: 10.1016/j.lungcan.2014.06.007. Epub 2014 Jul 7.

PMID:
25047676
16.

HER2 status in unusual histological variants of gastric adenocarcinomas.

Giuffrè G, Ieni A, Barresi V, Caruso RA, Tuccari G.

J Clin Pathol. 2012 Mar;65(3):237-41. doi: 10.1136/jclinpath-2011-200345. Epub 2011 Nov 8.

PMID:
22067088
17.

High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma.

Zhu YH, Yang F, Zhang SS, Zeng TT, Xie X, Guan XY.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2497-505. eCollection 2013.

18.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).

Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S.

Br J Cancer. 2015 Sep 1;113(5):716-21. doi: 10.1038/bjc.2015.279. Epub 2015 Aug 27. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1747.

19.

Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.

Xu CC, Yue L, Wei HJ, Zhao WW, Sui AH, Wang XM, Qiu WS.

Pathol Res Pract. 2013 Aug;209(8):479-85. doi: 10.1016/j.prp.2013.04.017. Epub 2013 Jun 7.

PMID:
23822993
20.

p95HER2 truncated form in resected non-small cell lung cancer.

Cappuzzo F, Cho YG, Sacconi A, Alì G, Siclari O, Incarbone M, Destro A, Terracciano L, Fontanini G, Marchetti A, Roncalli M, Varella-Garcia M.

J Thorac Oncol. 2012 Mar;7(3):520-7. doi: 10.1097/JTO.0b013e318249e13f. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.

Supplemental Content

Support Center